• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Clinical research and the Zika virus

Clinical research and the Zika virus

May 9, 2016
CenterWatch Staff

Zika, the latest public health threat, has been hot media buzz for a while now. What began in early 2015 in Brazil has spread to neighboring parts of Latin America, as well as islands in the Pacific. In January 2016, the World Health Organization (WHO) said the virus was likely to spread throughout most of the Americas by the end of the year. Will public awareness and fear of the disease spreading translate into rapid action on the part of clinical research? Probably not.

Cyclical outbreaks tend to drive public interest in clinical research for vaccines, but when it comes to public policy, these outbreaks are slow to motivate action. By the time researchers are able to bring a vaccine out of the lab and into the public, interest has often waned.

cww2018_20160509_k3T8fV-6

Remember the SARS outbreak of 2003? Roughly 8,098 people worldwide became sick and 774 died. In the years since that global panic, only one company has been able to get a viable candidate into a phase I clinical trial. Five other companies are still trying to create a SARS vaccine that can be tested in humans. A commercially available vaccine is still many years away, and public interest has moved on to other concerns, like Zika.

We will likely see the same pattern play out in the search for a Zika vaccine. President Obama has asked Congress for $1.8 billion to battle the Zika virus. Others want to use the money previously set aside for the Ebola crisis, ostensibly because the outbreak of 2014 in West Africa is no longer an imminent threat.

Government leadership is essential to motivate clinical research because they offer the most monetary support. The dominant pharmaceutical players in the $22 billion global vaccines market, such as Sanofi, GlaxoSmithKline, Merck, Pfizer and J&J, are often hesitant to partner with the government if funding isn’t certain.

Looking at other infectious diseases that impact the same region of the world, we should expect the development of a Zika vaccine to take some time. Dengue, a mosquito-borne virus that is a leading cause of illness and death in the tropics and subtropics, was first isolated by scientists over 70 years ago, yet we are only now seeing the first vaccine come to market. Sanofi, after two pivotal phase III trials, one in Southeast Asia and the other in Latin America, received its approval in Mexico, Brazil and the Philippines in 2015 under the brand name Dengvaxia. Sanofi intends to pursue approvals in all relevant countries, and other drug makers are following suit, with a number of candidate vaccines in phases I and II.

cww2018_20160509_k3T8fV-map

Similarly, malaria is on the verge of having its first vaccine made available globally. Primarily mosquito-borne, malaria is one of the most prevalent infectious diseases in the world with over 3.3 billion people living in at-risk areas, primarily in the tropics and subtropics. The malaria parasite was discovered in 1880, but it was only last summer that a malaria candidate vaccine from GSK received positive opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa. Mosquirix, the commercial name of the vaccine, is expected to be widely available in 2017.

While it could take years before an approved Zika vaccine reaches the market, there is reason to hope that clinical research will yield practical results in a more accelerated time frame. New technologies are changing the way vaccines are made, and recent advances have yielded promising results in similar diseases, like yellow fever, dengue and West Nile. Today, entire viral genomes can be cloned, enabling fast, custom design of organisms for use in vaccines. The future of vaccines will likely by dominated by this sort of genetic engineering.

The first vaccine trials against the Zika virus will likely start this fall, and in the best-case scenario, scientists can proceed to phase II by early 2017. But unless Congress approves the funds, health officials may not have enough money to put together a phase II trial, which would make the entire process longer and increase the risk of public interest being distracted by the next big outbreak of yet another infectious disease.

 

Matthew Howes is executive vice president, Strategy & Growth for PALIO. A leader in digital strategy, he has provided the fuel for digital businesses visited by over 100 million people every month. Email matthew.howes@inventivhealth.com.

This article was reprinted from CWWeekly, a leading clinical research industry newsletter providing expanded analysis on breaking news, study leads, trial results and more. Subscribe »

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing